Sandbox/00007: Difference between revisions

Jump to navigation Jump to search
Line 151: Line 151:
{{Family tree|boxstyle=text-align: left; font-size: 90%; padding: 0px; border-top: 0px;| A10 | | | | | | | | |A10=<div style="background: #FA8072; color: #F8F8FF; padding: 15px;"><BIG>'''''Preload'''''</BIG>
{{Family tree|boxstyle=text-align: left; font-size: 90%; padding: 0px; border-top: 0px;| A10 | | | | | | | | |A10=<div style="background: #FA8072; color: #F8F8FF; padding: 15px;"><BIG>'''''Preload'''''</BIG>


❑&nbsp;&nbsp;'''Goal: [[PCWP|<span style="color: #FFFFFF;">PCWP</span>]] 15–18 mm Hg ± correct [[pulmonary congestion|<span style="color: #FFFFFF;">pulmonary congestion</span>]]'''
❑&nbsp;&nbsp;'''Goal: [[PCWP|<span style="color: #FFFFFF;">PCWP</span>]] 15–18 mm Hg'''
 
❑&nbsp;&nbsp;'''± Correct [[pulmonary congestion|<span style="color: #FFFFFF;">pulmonary congestion</span>]]'''


: ❑&nbsp;&nbsp;↑ [[PCWP|<span style="color: #FFFFFF;">PCWP</span>]] by [[Normal saline|<span style="color: #FFFFFF;">normal saline</span>]] 100–200 mL IV bolus
: ❑&nbsp;&nbsp;↑ [[PCWP|<span style="color: #FFFFFF;">PCWP</span>]] by [[Normal saline|<span style="color: #FFFFFF;">normal saline</span>]] 100–200 mL IV bolus

Revision as of 02:39, 27 April 2014

Cardiogenic Shock
Resident Survival Guide
Overview
Causes
FIRE
Diagnosis
Treatment
Do's
Don'ts

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, MBChB. [2]

Overview

The clinical definition of cardiogenic shock includes decreased cardiac output with evidence of tissue hypoxia in the presence of adequate intravascular volume.[1]

Causes

Life Threatening Causes

Cardiogenic shock is a life-threatening condition and must be treated as such irrespective of the underlying cause.

Common Causes

  • Arrhythmic
  • Mechanical
  • Myopathic
  • Pharmacologic

Click here for the complete list of causes.

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.[2]

Boxes in the red signify that an urgent management is needed.

Abbreviations: CBC, complete blood count; CI, cardiac index; CK-MB, creatine kinase MB isoform; CVP, central venous pressure; DC, differential count; ICU, intensive care unit; INR, international normalized ratio; LFT, liver function test; MAP, mean arterial pressure; MVO2, mixed venous oxygen saturation; PCWP, pulmonary capillary wedge pressure; PT, prothrombin time; PTT, partial prothrombin time; SaO2, arterial oxygen saturation; SBP, systolic blood pressure; ScvO2, central venous oxygen saturation; SMA-7, sequential multiple analysis-7.

 
 
 
 
Does the patient have cardinal findings that increase the pretest probability of cardiogenic shock?

❑  Evidence of end-organ hypoperfusion

❑  Altered mental status
❑  Cold extremities
❑  Cyanosis
❑  Oliguria (urine output <0.5 mL/kg/h)
❑  Sustained hypotension
❑  SBP <90 mm Hg for ≥30 min or
❑  MAP ↓ >30 mm Hg below baseline for ≥30 min
❑  Presence of myocardial dysfunction after exclusion or correction of non-myocardial factors contributing to tissue hypoperfusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiogenic shock suspected
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immediate management (click for details)

❑  Intubation with mechanical ventilation

❑  ± Norepinephrine IV infusion 0.1–2.0 μg/kg/min
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiogenic shock confirmed
(click for details on criteria)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hemodynamic Optimization (click for details)
 
 
 
 
 
 
 
 
Preload

❑  Goal: PCWP 15–18 mm Hg

❑  ± Correct pulmonary congestion

❑  ↑ PCWP by normal saline 100–200 mL IV bolus
❑  ↓ PCWP by furosemide 40 mg slow IV injection
❑  ± Morphine 2–4 mg slow IV injection
 
 
 
 
 
 
 
 
Afterload

❑  Goal: MAP >60 mm Hg, SVR 800–1200 dyn·s·cm−5

❑  If ↑ MAP & ↑ SVR: wean vasopressors ± vasodilators
❑  If ↓ MAP & ↑ SVR: vasopressors + inotropes
❑  If ↓ MAP & ↓ SVR: vasopressors ± vasopressin
 
 
 
 
 
 
 
 
Cardiac Index

❑  Goal: CI >2.2 L/min/m2

❑  ± Dobutamine
❑  ± Milrinone
❑  ± IABP, VAD, or ECMO if refractory
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immediate goals for oxygenation and perfusion

❑  SaO2 >90%–92%

❑  CVP 8–12 mm Hg

❑  MVO2 >60%

❑  ScvO2 >70%

❑  Hemoglobin >7–9 g/dL

❑  Lactate <2.2 mM/L

❑  Urine output >0.5 mL/kg/h

❑  ± Correct arrhythmia

❑  ± Correct electrolyte disturbance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute myocardial infarction likely? (click for details)

❑  Positive cardiac biomarkers (cTnT, cTnI, or CK-MB)

❑  Symptoms of myocaridal ischemia

❑  New significant ECG findings of myocardial ischemia

 
YES, then manage as
UA/NSTEMI
and proceed to
acute ischemia pathway
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No, then proceed to
complete diagnostic approach
 
 
 
 
 
 
 
 

Acute Ischemia Pathway

Complete Diagnostic Approach

Treatment

Do's

Immediate management [Return to FIRE]

  • Dosage and Administration
  • Contraindications

Criteria for Cardiogenic Shock [Return to FIRE]

Hemodynamic Optimization [Return to FIRE]

PCWP (mm Hg) Phase of Pulmonary Congestion Findings on Chest Radiograph
18–20 Onset of pulmonary congestion Redistribution of pulmonary flow to the upper lobes ("cephalization") and Kerley lines
20–25 Moderate congestion Diminished clarity of the borders of medium-sized pulmonary vessels ("perihilar haze")
25–30 Severe congestion Radiolucent grapelike clusters surrounded by radiodense fluid ("periacinar rosette")
>30 Onset of pulmonary edema Coalescence of periacinar rosettes resulting in "Bat's wing" opacities
  • Dosage and Administration
  • For acute pulmonary edema, the initial dose is 40 mg injected slowly intravenously (over 1 to 2 minutes).
  • If a satisfactory response does not occur within 1 hour, the dose may be increased to 80 mg injected slowly intravenously (over 1 to 2 minutes).
  • Contraindications
  • Dosage and Administration
  • Slow IV injection 2–4 mg (over 1–5 minutes) every 5–30 minutes as needed.
  • Contraindications




Criteria for Acute Myocardial Infarction [Return to FIRE]

  • Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and with at least one of the following:[14]

Don'ts

References

  1. 1.0 1.1 1.2 Califf, RM.; Bengtson, JR. (1994). "Cardiogenic shock". N Engl J Med. 330 (24): 1724–30. doi:10.1056/NEJM199406163302406. PMID 8190135. Unknown parameter |month= ignored (help)
  2. Robin, E.; Costecalde, M.; Lebuffe, G.; Vallet, B. (2006). "Clinical relevance of data from the pulmonary artery catheter". Crit Care. 10 Suppl 3: S3. doi:10.1186/cc4830. PMID 17164015.
  3. "NOREPINEPHRINE BITARTRATE INJECTION".
  4. 4.0 4.1 4.2 Handbook of Emergency Cardiovascular Care for Healthcare Providers. ISBN 1616690003.
  5. Hollenberg, SM.; Kavinsky, CJ.; Parrillo, JE. (1999). "Cardiogenic shock". Ann Intern Med. 131 (1): 47–59. PMID 10391815. Unknown parameter |month= ignored (help)
  6. 6.0 6.1 Goldberg, RJ.; Gore, JM.; Alpert, JS.; Osganian, V.; de Groot, J.; Bade, J.; Chen, Z.; Frid, D.; Dalen, JE. (1991). "Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988". N Engl J Med. 325 (16): 1117–22. doi:10.1056/NEJM199110173251601. PMID 1891019. Unknown parameter |month= ignored (help)
  7. 7.0 7.1 Forrester, JS.; Diamond, G.; Chatterjee, K.; Swan, HJ. (1976). "Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts)". N Engl J Med. 295 (24): 1356–62. doi:10.1056/NEJM197612092952406. PMID 790191. Unknown parameter |month= ignored (help)
  8. 8.0 8.1 Forrester, JS.; Diamond, G.; Chatterjee, K.; Swan, HJ. (1976). "Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts)". N Engl J Med. 295 (25): 1404–13. doi:10.1056/NEJM197612162952505. PMID 790194. Unknown parameter |month= ignored (help)
  9. 9.0 9.1 Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter |month= ignored (help)
  10. Crexells, C.; Chatterjee, K.; Forrester, JS.; Dikshit, K.; Swan, HJ. (1973). "Optimal level of filling pressure in the left side of the heart in acute myocardial infarction". N Engl J Med. 289 (24): 1263–6. doi:10.1056/NEJM197312132892401. PMID 4749545. Unknown parameter |month= ignored (help)
  11. "FUROSEMIDE INJECTION [AMERICAN REGENT, INC.]".
  12. "MORPHINE SULFATE INJECTION, SOLUTION, CONCENTRATE".
  13. O'Connor, RE.; Brady, W.; Brooks, SC.; Diercks, D.; Egan, J.; Ghaemmaghami, C.; Menon, V.; O'Neil, BJ.; Travers, AH. (2010). "Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S787–817. doi:10.1161/CIRCULATIONAHA.110.971028. PMID 20956226. Unknown parameter |month= ignored (help)
  14. Thygesen, K.; Alpert, JS.; Jaffe, AS.; Simoons, ML.; Chaitman, BR.; White, HD.; Thygesen, K.; Alpert, JS.; White, HD. (2012). "Third universal definition of myocardial infarction". J Am Coll Cardiol. 60 (16): 1581–98. doi:10.1016/j.jacc.2012.08.001. PMID 22958960. Unknown parameter |month= ignored (help)